Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 20/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 12/20 | 1.00 |
| ▸ | HTR2B | P41595 | 17/20 | 0.88 |
| ▸ | HTR2A | P28223 | 16/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7042581 | 0.93 | HTR2C (1.00) | HTR2CCYP1A2HTR2BHTR2A | |
| SCHEMBL7039617 | 0.88 | HTR2C (1.00) | HTR2CCYP1A2HTR2BHTR2A | |
| SCHEMBL7039767 | 0.87 | HTR2C (1.00) | HTR2CCYP1A2HTR2BHTR2A | |
| SCHEMBL7039755 | 0.86 | HTR2C (1.00) | HTR2CCYP1A2HTR2BHTR2A | |
| SCHEMBL7039482 | 0.85 | HTR2C (1.00) | HTR2CCYP1A2HTR2BHTR2A | |
| SCHEMBL7041608 | 0.84 | HTR2C (0.82) | HTR2CCYP1A2HTR2BHTR2A | |
| SCHEMBL7042693 | 0.82 | HTR2C (1.00) | HTR2CCYP1A2HTR2BHTR2A | |
| SCHEMBL7084100 | 0.81 | HTR2C (0.78) | HTR2CCYP1A2HTR2BHTR2A | |
| SCHEMBL25434829 | 0.80 | HTR2C (0.76) | HTR2CCYP1A2HTR2BHTR2A | |
| SCHEMBL7042431 | 0.80 | HTR2C (0.87) | HTR2CCYP1A2HTR2BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030105139-A1 | Indole derivatives as 5-HT receptor antagonist | SMITHKLINE BEECHAM P.L.C. | 2003-06-05 | — | — | US | claimed |
| EP-0808312-B1 | INDOLE DERIVATIVES AS 5-HT RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM PLC (GB) | 2000-11-02 | — | — | EP | claimed |
| WO-1996023783-A1 | INDOLE DERIVATIVES AS 5-HT RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM PLC (GB) | 1996-08-08 | — | — | WO | claimed |
| US-6638953-B2 | Central nervous system disorders; anxiety | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-10-28 | — | — | US | disclosed |
| US-20030105139-A1 | Indole derivatives as 5-HT receptor antagonist | SMITHKLINE BEECHAM P.L.C. | 2003-06-05 | — | — | US | disclosed |
| WO-2003011281-A1 | TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER OR ATTENTION DEFICIT DISORDER | VERNALIS RESEARCH LIMITED (GB) | 2003-02-13 | — | — | WO | disclosed |
| US-6235758-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-05-22 | — | — | US | disclosed |
| EP-0808312-B1 | INDOLE DERIVATIVES AS 5-HT RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM PLC (GB) | 2000-11-02 | — | — | EP | disclosed |
| US-5990133-A | TREATING CENTRAL NERVOUS SYSTEM DISORDERS SUCH AS ANXIETY OR DEPRESSION | SMITHKLINE BEECHAM P.L.C. (GB) | 1999-11-23 | — | — | US | disclosed |
| EP-0808312-A1 | INDOLE DERIVATIVES AS 5-HT RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM PLC (GB) | 1997-11-26 | — | — | EP | disclosed |
| WO-1996023783-A1 | INDOLE DERIVATIVES AS 5-HT RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM PLC (GB) | 1996-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105139-A1 | Indole derivatives as 5-HT receptor antagonist | HTR5A, HTR2C, HTR1A | HTR2C 2/4885CYP1A2 392/4885HTR2B 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.